Metformin potentiates arsenic disulfide in diffuse large B-cell lymphoma: modulation of BAX/BCL-2 apoptotic pathway and hedgehog pathway
Abstract
Background: Arsenic disulfide (As2S2) inhibits proliferation and induces apoptosis in diffuse large B-cell lymphoma (DLBCL) cells, its clinical application is constrained by toxicity. Metformin has also been reported to exert antitumor effects across various malignancies. This study investigated whether metformin potentiates the anti-lymphoma efficacy of As2S2 in DLBCL cells and evaluated associated alterations in apoptosis-related markers and Hedgehog signaling molecules.
Methods: DLBCL cell lines (DB and SU-DHL-4) were treated with metformin and/or As2S2. Cell viability was assessed using the Cell Counting Kit-8 (CCK-8) assay, apoptosis was determined by Annexin V/propidium iodide (PI) flow cytometry, and drug interactions were analyzed using the Bliss independence model and CompuSyn software. The expression levels of BAX, BCL-2, SMO, GLI1, and GLI2 were analyzed by quantitative real-time PCR and Western blotting.
Results: Both metformin and As2S2 inhibited DLBCL cell proliferation in a dose- and time-dependent manner. Combination treatment resulted in significantly greater growth inhibition in both cell lines compared with either monotherapy, with synergistic effects confirmed by both Bliss and CompuSyn analyses. Furthermore, the combination significantly increased apoptosis relative to single-agent treatments. At the molecular level, combined treatment was associated with a pro-apoptotic shift in the BAX/BCL-2 ratio and downregulation of Hedgehog pathway components,…
Read the paper
Related studies
- Metformin as an adjuvant in breast cancer treatment
- Metformin Lysosomal Targeting: A Novel Aspect to Be Investigated for Metformin Repurposing in Neurodegenerative Diseases?
- Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
- Metformin induces ZFP36 by mTORC1 inhibition in cervical cancer-derived cell lines
- Protein Interaction Network for Identifying Vascular Response of Metformin (Oral Antidiabetic)
- Preventing Long COVID With Metformin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.